ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.9
  1. ホーム
  2. /化合物

ビタミンK-1

Phylloquinone

HCID 5284607
ノートを作成反応を作成見積依頼を出す印刷プレビュー

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
11104-38-4
標準SMILES
CC1=C(C/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=O)c2ccccc2C1=O
InChIKey
MBWXNTAXLNYFJB-NKFFZRIASA-N
分子式
C31H46O2
平均分子量
450.7 g/mol
単同位体質量
450.34978071

概要

Phylloquinone is a member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones. It has a role as a cofactor, a plant metabolite and a human metabolite. It is a member of phylloquinones and a vitamin K.

名称と識別子

優先名称
Phylloquinone
IUPAC
2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
現地名
ビタミンK-1
英語名
Vitamin K1
分子式
C31H46O2
分子量
450.702

名称と別名

VITAMIN K1phytonadione84-80-0PhylloquinonePhytomenadionePhytylmenadioneMephyton3-PhytylmenadioneMonodionSynthex PPhyllochinonKinadion
名称をさらに表示
ビタミンK-1Vitamin K1 (9CI, ACI)
KephtonMono-KayCombinal K1FitomenadionaKativ Nalpha-Phylloquinonetrans-PhylloquinoneK-Ject

データベース識別子

CAS
11104-38-4、79083-00-4、84-80-0
PubChem CID
5284607
DTXSID
DTXSID8023472
ChEMBL
CHEMBL1550
ChEBI
CHEBI:18067
UNII
MLF3D1712D、S5Z3U87QHF
EC Number
201-564-2、234-330-3、279-052-3
Nikkaji
J3.883K

物性

構造計算による物性補完中

XLogP
10.9
極性表面積
34.1 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
14
重原子数
33
形式電荷
0
複雑度
696

実験および物理化学的性質

Chemical ClassesBiological Agents -> Vitamins and Derivatives
DrugsPharmaceuticals -> Listed in ZINC15
LipidsLipids -> Prenol Lipids [PR] -> Quinones and hydroquinones [PR02] -> Vitamin K [PR0203]
CosmeticsSkin conditioning
pHSOLN OF 1 PART VIT K1 & 20 PARTS ALC IS NEUTRAL TO LITMUS
SpringerMaterials PropertiesChemical diffusion
OdorOdorless
Density0.964 @ 25 °C/25 °C
Color/Form · 4 件

Yellow viscous oil

LIGHT-YELLOW SOLIDS OR OILS

Pale yellow oil or yellow crystals

Clear, yellow to amber, viscous, odourless liquid

Solubility · 4 件

Insoluble in water

Colorless oil; UV max (95% alcohol): 259, 305 nm (log Em 3.79, 3.31); insol in water /2,3-Epoxide/

Insoluble in water; sparingly soluble in methanol; sol in ethanol; sol in acetone, benzene, petroleum ether, hexane, and dioxane; sol in chloroform, and other fat solvents; sol in vegetable oils

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 13.7% (17 of 124) of reports.

Warning

H317 (83.9%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P261, P272, P273, P280, P302+P352, P321, P333+P317, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 124 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 3 件

Chemical: 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, [R-[R*,R*-(E)]]-

Regulation (EC) No 1831/2003 (amended)

Vitamin K1: Does not have an individual approval but may be used under an appropriate group standard

Hazards Summary · 1 件

Reports of allergic contact dermatitis from cosmetic products; Although the risk for sensitization from cosmetic products containing 1% Vitamin K1 cannot be quantified from the available data, case reports show that Vitamin K1 is a contact allergen in man. In cases of pre-existing sensitization acquired by topical application of Vitamin K1 present in cosmetics, an individual might not be able to receive Vitamin K1 therapeutically or experience allergic reactions upon Vitamin K1 treatment. Therefore, the SCCS considers that vitamin K1 is not safe when used in cosmetic product in a concentration up to 1%. [SCCS (Scientific Committee on Consumer Safety), Opinion on vitamin K1 (phytonadione), 23 March 2010] Severe hypersensitivity reactions have been reported after IV and IM injection; [Olson, p. 633-4] May cause irritation; [Sigma-Aldrich MSDS]

FDA Requirements · 2 件

The US Food and Drug Administration ... requires that all infant formula sold in the USA contain a minimum of 4 ug/100 kcal (0.2 mg/kg) of vitamin K; and that any vitamin K added shall be in the form of phylloquinone.

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl phytonadione, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

化学と産業

薬理情報

ATC Code · 4 件

B02BA01

B - Blood and blood forming organs

QB - Blood and blood forming organs

B02BA01

Bionecessity · 3 件

The discovery of a vitamin K dependent protein in bone suggests that the fetal bone abnormalities associated with the administration of oral anticoagulants during the first trimester of pregnancy "fetal warfarin syndrome" may be related to a deficiency of the vitamin. /Vitamin K/

State of deficiency: chief clinical manifestation of vitamin k deficiency is increased tendency to bleed, and postoperative hemorrhage are common; intracranial hemorrhage may occur. /vit k/

Hypoprothrombinemia secondary to vitamin K deficiency may occur in the following persons or conditions: Patients with hepatic or biliary tract disease, including obstructive jaundice or biliary fistula; in malabsorption syndromes or diseases affecting the small intestine or pancreas, such as celiac disease, cystic fibrosis, intestinal resuction, persistent diarrhea or dysentery, regional enteritis, sprue, or ulcerative colitis; prolonged T-tube drainage; abetalipoproteinemia; patients receiving total parenteral nutrition (TPN); or in infants receiving unfortified milk substitute formulas or those who are exclusively breast-fed. Also vitamin K deficiency may occur when vitamin K activity is impaired by sulfonamides, quinine, quinidine, or dactinomycin, or when absorption is decreased by concurrent administration of cholestyramine, colestipol, mineral oil, or sucralfate. /Vitamin K/

Pharmacodynamics · 1 件

Phylloquinone is a vitamin K indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity of vitamin K. It has a long duration of action as vitamin K is cycled in the body, and a wide therapeutic index as large doses can be tolerated. Patients should have their prothrombin time monitored during therapy and healthcare professionals should be aware of the increased risk of hypersensitivity reactions with parenteral administration.

Mechanism of Action · 4 件

Vitamin K is a cofactor of gamma-carboxylase. Gamma carboxylase attaches carboxylic acid functional groups to glutamate, allowing precursors of factors II, VII, IX, and X to bind calcium ions. Binding of calcium ions converts these clotting factors to their active form, which are then secreted from hepatocytes into the blood, restoring normal clotting function. Vitamin K may also carboxylate matrix proteins in chondrocytes, inhibiting calcification of joints, and may increase type II collagen. The role of vitamin K in osteroarthritis, bone density, and vascular calcification is currently under investigation.

サプライヤー

読み込み中…

公開中の見積依頼

読み込み中…

関連反応

1 件
反応記録を作成
HRID 569712 の反応式
HRID 569712反応物としてuspto-grants-1988_03

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

SOL IN FATS

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Vitamins; Antifibrinolytic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Medicines affecting coagulation

Boiling Point140-145 °C @ 0.001 mm Hg

物理化学的性質

化粧品成分の機能
スキンコンディショニング - その他
InChIKey
MBWXNTAXLNYFJB-OJUGCUFGNA-N
SMILES
C12C=CC=CC=1C(=O)C(C)=C(C/C=C(\C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C2=O |&1:18,23,r|
Hazard Classes and CategoriesSkin Sens. 1B (83.9%)

安全と保護具

Storage Conditions · 2 件

KEEP WELL CLOSED & PROTECTED FROM LIGHT.

The drug is photosensitive and must be protected from light at all times. Infusion solutions should be protected from light by wrapping the container with aluminum foil or other opaque material. Phytonadione tablets should be stored in well-closed, light-resistant containers.

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 5 件

Vit k antagonizes inhibitory effect of /acenocoumarol, phenprocoumon, anisindione, diphenadione, & phenindione/ on hepatic synthesis of vit k-dependent clotting proteins... /vit k/

Requirements for vitamin K may be increased in patients receiving /broad-spectrum antibiotics, moxalactam, quinidine, quinine, high doses of salicylates, or antibacterial sulfonamides/.

Concurrent use /with dactinomycin/ may decrease the effects of vitamin K; evidence is inconclusive, observation of patients is recommended and a higher dose of vitamin K may be required. /Vitamin K/

Concurrent use /of coumarin- or indandione-derivative anticoagulants/ with vitamin K may decrease the effects of these anticoagulants as a result of increased hepatic synthesis of procoagulant factors. When reinstituting oral anticoagulant therapy after the administration of large doses of vitamin K, it may be necessary to temporarily increase the dose of the oral anticoagulant, or to use one such as heparin that acts on a different principle. /Vitamin K/

For more Interactions (Complete) data for PHYTONADIONE (18 total), please visit the HSDB record page.

Adverse EffectsMost adverse effects from phytonadione occur with IV, SQ, and IM administration:
Exposure Routes · 1 件

Subcutaneous, Intramuscular, Intravenous injection. Oral phylloquinone is adequately absorbed from the gastrointestinal tract only if bile salts are present. After absorption, phylloquinone is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues.

Toxicity Summary · 2 件

Doses up to 50 mg have been used. The majority of toxicity occurs when given by IV.

Vitamin K is an essential cofactor for the gamma-carboxylase enzymes which catalyze the posttranslational gamma-carboxylation of glutamic acid residues in inactive hepatic precursors of coagulation factors II (prothrombin), VII, IX and X. Gamma-carboxylation converts these inactive precursors into active coagulation factors which are secreted by hepatocytes into the blood. Supplementing with Phylloquinone results in a relief of vitamin K deficiency symptoms which include easy bruisability, epistaxis, gastrointestinal bleeding, menorrhagia and hematuria.

Natural Pollution Sources · 2 件

FAT-SOL VIT OCCURRING NATURALLY AS TRANS ISOMER. ... FIRST ISOLATED FROM ALFALFA; ALSO SHOWS WIDESPREAD DISTRIBUTION IN HIGHER GREEN PLANTS: DAM ET AL, HELV CHIM ACTA 22, 310 (1939).

Phylloquinone is widely distributed in higher plants and in some blue-green algae. It is present in many foods, especially leafy green vegetables and some vegetable oils.

Human Toxicity Excerpts · 2 件

/HUMAN EXPOSURE STUDIES/ To determine whether vitamin K administration affects urinary calcium excretion in postmenopausal women. Before- and after-trials with a 2-week treatment period. Healthy postmenopausal women (55 to 75 years old) were recruited from the convents in and around Maastricht. Controls (25 to 40 years old) were healthy premenopausal volunteers. Daily administration of 1 mg of vitamin K for 2 weeks. Serum immunoreactive osteocalcin: hydroxylapatite binding (HAB) capacity of serum immunoreactive osteocalcin; excretion of calcium, hydroxyproline, and creatinine in the urine during the last 2 h of a 16-h fasting period. In premenopausal women, no effect of vitamin K administration was seen. In the postmenopausal group, vitamin K induced increased serum immunoreactive osteocalcin concentration; normalization of the HAB capacity of serum immunoreactive osteocalcin (this marker was less than 50% that of the controls in the pretreatment samples); a decrease in urinary calcium excretion, notably in the "fast losers" of calcium; and a parallel decrease in urinary hydroxyproline excretion in the fast losers of calcium. The serum immunoreactive osteocalcin level may vary with vitamin K status. This variance should be taken into consideration if osteocalcin is used as a marker for osteoblast activity. Vitamin K is one factor that may play a role in the loss of bone mass in postmenopausal osteoporosis.

/EPIDEMIOLOGY STUDIES/ A retrospective review of anaphylaxis after i.v. phytonadione over a 58-month period at a large academic center was performed. During the period of the study a protocol for the administration of i.v. phytonadione was in place. A review of computerized records and survey of staff identified cases of anaphylaxis meeting predefined inclusion criteria. In addition, a literature review was performed for articles concerning anaphylaxis after i.v. phytonadione. Over the 58 months of the study, a total of 6,572 doses of i.v. phytonadione were administered. Two cases of anaphylaxis after i.v. phytonadione were identified. The incidence of anaphylaxis was 3 per 10,000 doses with 95% confidence intervals of 0.04 to 11 per 10,000 doses. The literature review identified 14 cases meeting inclusion criteria with no reviews of the literature or estimates of incidence. The incidence of anaphylaxis after i.v. phytonadione is overall comparable or slightly less than other drugs known to cause anaphylaxis.

Carcinogen Classification3, not classifiable as to its carcinogenicity to humans. (L135)
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Phytonadione

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 4 件

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ The offspring of mice treated with phylloquinone by injection had cleft lip and exencephaly. Six pregnant Sprague-Dawley rats were dosed with 10 mg/kg body weight phylloquinone (Konakion) daily on days 9-20 of gestation, and the fetuses were delivered on day 21 and examined for external malformations and the presence of hemorrhages only. No adverse effects were noted when compared with a group of five untreated controls.

/GENOTOXICITY/ In fetal sheep that received a catheter in the femoral vein 10-15 days before term, phylloquinone significantly increased the frequency of sister chromatid exchange in peripheral blood lymphocytes sampled 24 hours later.

/GENOTOXICITY/ /Phytonadione/ ... at concentrations up to 2,000 mcg/plate with or without metabolic activation, was negative in the Ames microbial mutagen test.

/GENOTOXICITY/ /Phylloquinone/ ... enhanced the frequency of sister chromatid exchange in cultured human maternal lymphocytes at concentrations that are relevant in vivo, and a similar increase in sister chromatid exchange frequency was observed in cultured lymphocytes from human placental blood.

Populations at Special RiskSRP: Persons with bleeding disorders or who are taking anticoagulants should be protected from exposure.
Evidence for Carcinogenicity · 1 件

Evaluation: There is inadequate evidence in humans for the carcinogenicity of vitamin K. There is inadequate evidence in experimental animals for the carcinogenicity of vitamin K. Overall evaluation: Vitamin K is not classifiable as to its carcinogenicity to humans (Group 3). /Vitamin K/

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

法規制情報

FDA Requirements · 2 件

The US Food and Drug Administration ... requires that all infant formula sold in the USA contain a minimum of 4 ug/100 kcal (0.2 mg/kg) of vitamin K; and that any vitamin K added shall be in the form of phylloquinone.

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl phytonadione, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Vit k is necessary for formation of prothrombinogen & other blood clotting factors in liver. During clotting, circulating prothrombin is required for production of thrombin; in turn, thrombin converts fibrinogen to fibrin, network of which constitutes clot. /vit k/

In normal animals and man, phyltonadione ... /is/ virtually devoid of pharmacodynamic activity. In Animals and man deficient in vitamin k, the pharmacological action of vitamin k is identical to its normal physiological function, that is, to promote hepatic biosynthesis of prothrombin (factor ii), proconvertin (factor vii), plasma thromboplastin component (ptc, christmas factor, factor ix), and Stuart factor (factor x).

On the basis of studies of microsomal metabolism in vitro and studies in rats and mice in vivo, /it was suggested/ that vitamin K may be mutagenic by affecting the mixed-function oxidase system which metabolizes benzo(a)pyrene. Phylloquinone at a high concentration (200 umol/l) inhibited the conversion of benzo(a)pyrene to its more polar metabolites, ... . Paradoxically, at a lower concentration of phylloquinone (25 umol/l), ... the metabolism of benzo(a)pyrene was increased. In this system, therefore, .... phylloquinone could either potentiate or inhibit it, depending on the concentration. This overall weaker inhibitory effect of phylloquinone could be due to the low solubility of this lipophilic compound, but it is difficult to explain the mechanism of the enhanced metabolism of benzo(a)pyrene at lower concentrations of phylloquinone.

Biological Half-LifeIntravenous phylloquinone has an initial half life of 22 minutes, followed by a half life of 125 minutes.
Metabolism/Metabolites · 6 件

Phylloquinone's phytyl side chain is omega hydroxylated by CYP4F2. The side chain is then cleaved to 5 or 7 carbons long, and then glucuronidated prior to elimination. Vitamin Ks in general undergo a cycle of reduction to vitamin K hydroquinone by vitamin K epoxide reductase (VKOR), oxidation to vitamin K epoxide by gamma-glutamyl carboxylase, and converted back to vitamin K by VKOR.

...In experimental animals...phylloquinone...can be converted to more potent menaquinone series. Whether this can occur in man and of what significance these transformations are to action of phylloquinone...are still unknown.

In animals treated with warfarin, major fraction of phylloquinone is metabolized to phylloquinone oxide.

Phytonadione is rapidly metabolized to more polar metabolites, which are excreted in the bile and urine. The major urinary metabolites result from shortening of the side chain to five or seven carbon atoms, yielding carboxylic acids that are conjugated with glucuronate prior to excretion. Treatment with a coumarin-type anticoagulant results in a marked increase in the amount of phytonadione-2,3-epoxide in the liver and blood. Such treatment also increases the urinary excretion of phytonadione metabolites, primarily degradative products of phytonadione-2,3-epoxide. The biliary metabolites of phytonadione have not been identified.

The liver plays an exclusive role in the metabolic transformations leading to the elimination of vitamin K from the body. After intravenous doses of 45 ug to 1 mg (3)H-phylloquinone, about 20% of the radiolabel was excreted in the urine within three days, and 35-50% was excreted as metabolites in the feces via the bile.

Route of Elimination: Almost no free unmetabolized vitamin K appears in bile or urine.

FDA Pharmacological Classification · 6 件

A034SE7857

PHYTONADIONE

Physiologic Effects [PE] - Increased Prothrombin Activity

Physiologic Effects [PE] - Reversed Anticoagulation Activity

Chemical Structure [CS] - Vitamin K

Established Pharmacologic Class [EPC] - Vitamin K

MeSH Pharmacological Classification · 2 件

Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.

Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body.

Absorption, Distribution and Excretion · 6 件

A 4 µg oral dose of phylloquinone is 13% ± 9% bioavailable, with a Tmax of 4.7 ± 0.8 hours. 1.5 ± 0.8 nmol is found in the plasma compartment, and 3.6 ± 3.4 nmol is found in the second compartment. A 10 mg intramuscular phylloquinone dose is 89.2% ± 25.4% bioavailable. The same dose reaches a mean Cmax of 67 ± 30 ng/mL, with a mean Tmax of 9.2 ± 6.6 hours, and an AUC of 1700 ± 500 h\*ng/mL. A 10 mg intravenous phylloquinone dose has a mean AUC of 1950 ± 450 h\*ng/mL.

Intravenous phylloquinone is 36% eliminated in the feces in 5 days and 22% recovered in urine in 3 days.

The steady state volume of distribution of phylloquinone is 20 ± 6 L in subjects who are also taking phenprocoumon therapy.

Intravenous phylloquinone is 90% cleared in 2 hours, and 99% cleared in 8 hours. A 10 mg intravenous dose of phylloquinone has a mean clearance of 91 ± 24 mL/min.

Little is known about the excretion of vitamin K. High fecal concentrations of vitamin K probably result from bacterial synthesis in the intestine.

Although the drug may be concentrated in the liver for a short time after absorption, only small amounts of phytonadione are stored in body tissues.

Tissue LocationsLiver
Cellular LocationsCytoplasm
Metabolite PathwaysAcenocoumarol Action Pathway

用途と製造

Uses · 5 件

The major dietary source of vitamin K found in green plants, algae, and photosynthetic bacteria; Used as a vitamin (prothrombogenic) and veterinary antidote for dicoumarol poisoning; [Merck Index] Essential vitamin for the synthesis of coagulation factors II, VII, IX, and X in the liver; Used to reverse anticoagulation (prolonged prothrombin time) caused by coumarin and indanedione derivatives; [Olson, p. 633]

MEDICATION (VET)

MEDICATION

Use (kg; approx.) in Germany (2009): >25

For the treatment of haemorrhagic conditions in infants, antidote for coumarin anticoagulants in hypoprothrombinaemia.

Impurities · 2 件

Commercial preparations may contain up to 20% of the cis isomer.

Commercially available phylloquinone (vitamin K1) is prepared synthetically and may contain not only 2',3'-trans-phylloquinone (not less than 75%), but also 2',3'-cis-phylloquinone and trans-epoxyphylloquinone (not more than 4.0 percent). Phylloquinone occurs in nature only as the 2',3'-trans-7R,11R-stereoisomer.

Methods of Manufacturing · 3 件

Partial syntheses from menadione and phytol ... Synthesis using a pi-allylic nickel(I) complex ... .

Synthetically from 2-methyl-1,4-naphthoquinone and phytol.

The first syntheses and structural elucidation of phylloquinone were published in 1939 almost simultaneously by four groups. The starting materials were menadione or menadiol as the aromatic component and natural phytol or one of its derivatives. A breakthrough in commercial synthesis was achieved in the 1950s, when it was found that monoacylated menadiols (e.g. the monoacetate or the monobenzoate) could be used advantageously in the alkylation step and that natural phytol could be replaced by isophytol, which is easy to synthesize.

Formulations/Preparations · 5 件

PHYTONADIONE, USP (VIT K1, AQUAMEPHYTON, KONAKION, MEPHYTON)... MARKETED IN 5-MG TABLETS, & IN AMPULS CONTAINING EMULSION OF 2 OR 10 MG/ML OF PHYTONADIONE DISPERSED IN SOLN OF BUFFERED POLYSORBATE & PROPYLENE GLYCOL (KONAKION) OR POLYETHYLATED FATTY ACID DERIV & DEXTROSE (AQUAMEPHYTON).

KONAKION IS ADMIN ONLY IM; AQUAMEPHYTON MAY BE GIVEN BY ANY PARENTERAL ROUTE.

COLLOIDAL SOLN IS MARKETED UNDER NAME AQUA-MEPHYTON.

Oral tablets; 5 mg, Mephyton (scored) Merck.

For more Formulations/Preparations (Complete) data for PHYTONADIONE (6 total), please visit the HSDB record page.

Use ClassificationCosmetics -> Skin conditioning
General Manufacturing Information · 6 件

1,4-Naphthalenedione, 2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl]-: ACTIVE

PHYLLOQUINONE IS FOUND IN PLANTS; IT IS ONLY NATURAL VIT K AVAIL FOR THERAPEUTIC USE.

SYNTH YIELDS MIXT OF CIS & TRANS ISOMERS OF WHICH TRANS FORM PREDOMINATES. COMMERCIAL PREPN MAY CONTAIN UP TO 20% OF CIS ISOMER.

METABOLIC STUDIES: SHEARER ET AL, BRIT J HAEMATOL 18, 297 (1970); 22, 579 (1972). CIS ISOMER HAS LITTLE, IF ANY, VIT K ACTIVITY: MATSCHINER ET AL, J NUTR 102, 625 (1972).

DRUGS WITH VIT K ACTIVITY MAY BE CHEMICALLY ASSAYED & DO NOT REQUIRE BIOASSAY. ...DETERMINATION OF VIT K CONTENT OF FOODS, ASSAY BASED UPON ABILITY OF PREPN TO INCR PROTHROMBIC LEVEL OF DEFICIENT CHICKS IS EMPLOYED.

For more General Manufacturing Information (Complete) data for PHYTONADIONE (9 total), please visit the HSDB record page.

補足説明

定義本品は、次の化学式で表されるナフトキノン誘導体である。